Journal
EXPERT REVIEW OF ANTICANCER THERAPY
Volume 15, Issue 5, Pages 579-594Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737140.2015.1031218
Keywords
angiogenesis; FGF; nintedanib; non-small cell lung cancer; VEGF
Categories
Funding
- Boehringer Ingelheim
Ask authors/readers for more resources
Antiangiogenic agents are effective standard-of-care options in several malignancies, but are generally associated with only modest improvements in survival, as well as leading to additional toxicities. Furthermore, almost all patients develop acquired resistance to therapy, possibly due to the activation of alternative proangiogenic pathways. Here we discuss: the rationale for developing nintedanib, an agent that simultaneously inhibits signaling pathways activated by platelet-derived growth factor, FGF, as well as VEGF; how its distinctive inhibitory and pharmacokinetic profile could underlie promising efficacy and tolerability observed in Phase II trials in patients with relapsed/refractory non-small cell lung cancer, advanced ovarian cancer and metastatic colorectal cancer; the ongoing Phase III program that is assessing nintedanib in these areas of major unmet medical need; and recent progress in the development of biomarkers that may predict response to nintedanib.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available